Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax
December 20 2022 - 9:00AM
via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq:
GOVX), a biotechnology company developing immunotherapies and
vaccines against cancers and infectious diseases, announced today
the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse
School of Medicine President and CEO, as Special Advisor to the
Chairman/CEO and Board of Directors of GeoVax.
Dr. Montgomery Rice brings GeoVax exceptional
expertise and highly recognized experience at the highest levels of
healthcare leadership, patient care, biomedical research, and
public health policy.
“We are delighted Dr. Montgomery Rice is joining
in this unique advisory role for GeoVax’s growing ecosystem of
outstanding executives, advisors, board members, scientists, and
partners,” said David Dodd, GeoVax Chairman and CEO. “Her
organizational management acumen and career-long dedication to
advance medical training, health equity and other critical areas of
public health, will add dimension to our initiatives to expand
access to our investigational vaccines and immunotherapies against
life-threatening infectious diseases and cancers.”
Dr. Montgomery Rice has been a driving force
behind research, education and care that closes equity gaps in
healthcare, including women’s health. She currently serves as
President and Chief Executive Officer of the Morehouse School of
Medicine (MSM) in Atlanta and is the first woman in the
institution’s history to serve in this role. At MSM, she has also
served as Dean and Executive Vice President and professor of
Obstetrics and Gynecology. Prior to MSM, Dr. Montgomery Rice held a
number of faculty and leadership positions at Meharry Medical
College in Nashville, including professor and chair in the
Department of Obstetrics and Gynecology, Dean and Senior Vice
President of Meharry Medical College’s School of Medicine, and
Program Director of the OB-GYN Residency Training Program and
Founding Director of the Center for Women’s Health Research, one of
the nation’s first research centers devoted to studying diseases
that disproportionately impact women of color. Dr. Montgomery Rice
also served in faculty and leadership roles at University of Kansas
School of Medicine, Vanderbilt University Medical Center, and Henry
Ford Medical Center.
Dr. Montgomery Rice holds memberships in various
organizations and participates on several boards. She is an
Advisory Board Member of the Historically Black Colleges and
Universities Capital Financing Advisory Board. She also serves on
the board of directors for UnitedHealth Group, Wellpath, 23&Me,
Nemours, CARE USA, Josiah Macy Jr. Foundation, and the Moffit
Cancer Center. In 2021, Governor Brian Kemp appointed Dr.
Montgomery Rice to the Georgia Commission on Women, where she lends
her depth of knowledge and expertise as a women’s health researcher
to improve the life of women and their families in Georgia. In
March 2022, President Joe Biden appointed Dr. Montgomery Rice to
the President’s Committee on the National Medal of Science.
“I am particularly excited about GeoVax’s
innovative programs focused on providing the public protection from
the most pressing and emerging infectious disease threats,” said
Dr. Montgomery Rice. “I look forward to helping GeoVax as the
company progresses its vaccine and immunology programs toward
patients.”
Dedicated to the creation and advancement of
health equity, Dr. Montgomery Rice’s career has been recognized
with numerous accolades and honors, notably, the Horatio Alger
Award, the National Human Relations Award from the American Jewish
Committee Atlanta, the Dean Griffin Community Service Award from
the Georgia Institute of Technology, Girls Inc. 2019 Smart Award,
the National Medical Association OB/GYN 2019 Legend of the Section
Award, the Turknett Leadership Character Award, Visions of
Excellence Award from the Atlanta Business League, the Links
Incorporated Co-Founders Award, the Trumpet Vanguard Award, the
Dorothy I. Height Crystal Stair Award, National Coalition of 100
Black Women - Women of Impact, YWCA – Women of Achievement of
Atlanta and Nashville, American Medical Women’s Association
Elizabeth Blackwell Medal, and Working Mother Media Multicultural
Women’s Legacy Award.
Dr. Montgomery Rice holds a bachelor’s degree in
chemistry from the Georgia Institute of Technology, a medical
degree from Harvard Medical School, an honorary degree from the
University of Massachusetts Medical School, and a Doctor of Humane
Letters honorary degree from Rush University.
About GeoVaxGeoVax Labs, Inc. is a
clinical-stage biotechnology company developing novel therapies and
vaccines for cancers and many of the world’s most threatening
infectious diseases. The company’s lead program in oncology is a
novel oncolytic solid tumor gene-directed therapy, Gedeptin®,
presently in a multicenter Phase 1/2 clinical trial for advanced
head and neck cancers. GeoVax’s lead infectious disease candidate
is GEO-CM04S1, a next-generation COVID-19 vaccine targeting
high-risk immunocompromised patient populations. Currently in two
Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a
single-dose, COVID-19 vaccine for immunocompromised patients such
as those suffering from hematologic cancers and other patient
populations for whom the current authorized COVID-19 vaccines are
insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical
trial evaluating the vaccine as a more robust, durable COVID-19
booster among healthy patients who previously received the mRNA
vaccines. GeoVax has a leadership team who have driven significant
value creation across multiple life science companies over the past
several decades. For more information, visit our website:
www.geovax.com.
Media Relations Contact:Gina Cestari6
Degrees917-797-7904 gcestari@6degreespr.com
Investor Relations Contact:Rich CockrellCG
Capital404-736-3838 govx@cg.capital
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Jun 2024 to Jul 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Jul 2023 to Jul 2024